Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: An insight into current clinical practice

Transplant International

Volumn 28, Issue 9, 2015, Pages 1042-1054

  Fernández Ruiz, Mario ^a   Arias, Manuel ^b   Campistol, Josep M ^c   Navarro, David ^d   Gõmez Huertas, Ernesto ^e   Gõmez Márquez, Gonzalo ^f   Díaz, Juan Manuel ^g   Hernández, Domingo ^h   Bernal Blanco, Gabriel ⁱ   Cofan, Frederic ^c   Jimeno, Luisa ^j   Franco Esteve, Antonio ^k   González, Esther ^a   Moreso, Francesc J ^l   Gõmez Alamillo, Carlos ^b   Mendiluce, Alicia ^m   Luna Huerta, Enrique ⁿ   Aguado, José María ^a  

^a Universidad Complutense   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g FUNDACIÓ PUIGVERT   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

ⁿ HOSPITAL INFANTA CRISTINA   (Spain)

more..

Author keywords

antiviral prophylaxis; cytomegalovirus; kidney transplantation; multicenter study; preemptive therapy; seropositive recipient

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; SPAIN; TREATMENT DURATION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GLOMERULUS FILTRATION RATE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY; RISK FACTOR;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; SPAIN;

EID: 84938750282     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12586     Document Type: Article

References (45)

1. Razonable RR, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 4): 93.
2. Freeman RB Jr,. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9: 2453.
3. Bate SL, Dollard SC, Cannon MJ,. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50: 1439.
4. Lopo S, Vinagre E, Palminha P, Paixao MT, Nogueira P, Freitas MG,. Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003. Euro Surveill 2011; 16: pi=19896.
5. de Ory F, Ramirez R, Garcia Comas L, Leon P, Sagues MJ, Sanz JC,. Is there a change in cytomegalovirus seroepidemiology in Spain? Eur J Epidemiol 2004; 19: 85.
6. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
7. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
8. Winston DJ, Saliba F, Blumberg E, et al,. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12: 3021.
9. Khoury JA, Storch GA, Bohl DL, et al,. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
10. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F,. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
11. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V,. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69.
12. Witzke O, Hauser IA, Bartels M, et al,. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93: 61.
13. de la Torre-Cisneros J, Fariñas MC, Castõn JJ, et al,. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735.
14. Kotton CN, Kumar D, Caliendo AM, et al,. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333.
15. Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD,. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013; 95: 1455.
16. Manuel O, Asberg A, Pang X, et al,. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009; 49: 1160.
17. Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
19. European Renal Association, European Society for Organ Transplantation. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000; 15 (Suppl. 7): 1.
20. Austin PC,. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399.
21. Luan FL, Kommareddi M, Ojo AO,. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation 2011; 91: 237.
22. Delgado JF, Manito N, Almenar L, et al,. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011; 13: 136.
23. Atabani SF, Smith C, Atkinson C, et al,. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457.
24. Wadhawan M, Gupta S, Goyal N, et al,. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Liver Transpl 2012; 18: 1448.
25. Manuel O, Kralidis G, Mueller NJ, et al,. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402.
26. Sagedal S, Hartmann A, Nordal KP, et al,. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
27. Carstens J, Andersen HK, Spencer E, Madsen M,. Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis 2006; 8: 203.
28. Bataille S, Moal V, Gaudart J, et al,. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl Infect Dis 2010; 12: 480.
29. San Juan R, Aguado JM, Lumbreras C, et al,. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875.
30. Gabardi S, Asipenko N, Fleming J, et al,. Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation 2015 Jan 30 [epub ahead of print].
31. Stevens DR, Sawinski D, Blumberg E, et al,. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015; 17: 163.
32. Razonable RR, Hayden RT,. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 2013; 26: 703.
33. Pang XL, Fox JD, Fenton JM, et al,. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9: 258.
34. Caliendo AM, Shahbazian MD, Schaper C, et al,. A commutable cytomegalovirus calibrator is required to improve the agreement of viral load values between laboratories. Clin Chem 2009; 55: 1701.
35. Hirsch HH, Lautenschlager I, Pinsky BA, et al,. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56: 367.
36. Pescovitz MD, Rabkin J, Merion RM, et al,. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
37. Boivin G, Goyette N, Gilbert C, et al,. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615.
38. Boivin G, Goyette N, Farhan M, Ives J, Elston R,. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53: 208.
39. Florescu DF, Qiu F, Schmidt CM, Kalil AC,. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 2014; 58: 785.
40. Jamal AJ, Husain S, Li Y, Famure O, Kim SJ,. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients. Transplantation 2014; 97: 569.
41. Humar A, Limaye AP, Blumberg EA, et al,. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427.
42. Opelz G, Dohler B, Ruhenstroth A,. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 928.
43. Meije Y, Fortun J, Len O, et al,. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 2014; 16: 387.
44. Stern M, Hirsch H, Cusini A, et al,. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98: 1013.
45. Walker JD, Maier CL, Pober JS,. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. J Immunol 2009; 182: 1548.